İlkay BAHÇECİ, Uğur KOSTAKOGLU, Ömer Faruk DURAN, İlknur Esen YILDIZ, Aziz Ramazan DİLEK

Çeşitli Klinik Örneklerden İzole Edilen Stenotrophomonas maltophilia Suşlarının Dağılımı ve Antimikrobiyal Duyarlılıkları: 8 Yılık Çalışma

Amaç: Hastane enfeksiyonları ve buna bağlı mortalitenin artması çoklu ilaç direncine sahip fırsatçı patojenleri her zamankinden daha fazla gündeme getirmiştir. Bunlar arasında yer alan stenotrophomonas maltophilia önemi giderek artan fırsatçı bir patojendir. Bu çalışmanın amacı,sekiz yıllık süre boyunca hastanemizde çeşitli klinik örneklerden izole edilmiş S. maltophilia izolatlarının dağılımını ve antimikrobiyal duyarlılıklarını araştırmaktır.Yöntemler: Ocak 2011-Aralık 2019 tarihleri arasında çeşitli klinik örneklerden izole edilen toplam 149 S. maltophilia suşunun antimikrobiyallere direnç oranları araştırıldı. Bakteri identifikasyonu ve antibiyotik duyarlılığı rutin konvansiyonel mikrobiyolojik yöntemler ve VİTEK 2 kompakt otomatize sistem (BioMerieux, France) ile yapılmıştır.Bulgular: S. maltophilia en sık yoğun bakım ünitelerinde izole edilirken 50 (%33,5), en az 1 örnekle ( %0,6) Kardiyovasküler cerrahi servisi, Pediatri servisinden izolasyon gerçekleşmiştir. Örneklerin 85’i (%57,) solunum yolu izolatları olurken (trakeal aspirat, lavaj, balgam), en az 1 örnek ( %0,6) ile plevra ve eklem sıvısı olmuştur. Karbapenemlere doğal direnç gösteren S. maltophilia’da levofloksasin direnci % 6 iken, trimetoprim/sulfametoksazol’de %12, seftazidim’de %45 olarak tespit edilmiştir.Tartışma ve Sonuç: Çalışmada saptanan yüksek direnç oranları nedeniyle, S. maltophilia suşlarının etken olduğu nozokomiyal enfeksiyonların tedavisinde mümkün olduğunca in vitro duyarlılık testlerinin yapılması gerekir. Bunun yapılamadığı durumlarda ise tedavi planlamasında trimetoprim-sulfametoksazol ve levofloksasin iyi birer tedavi seçeneğidir. Ayrıca tedaviye başlamadan önce kolonizasyon - etken ayrımı klinik bulgularda göz önünde tutularak birlikte karar verilmelidir.

Distribution and Antimicrobial Susceptibilities of Stenotrophomonas maltophilia Strains Isolated from Various Clinical Samples: An 8-Year Study

Objective: Hospital infections which associated with increased mortality have brought opportunistic pathogens like Stenotrophomonas maltophilia, with multiple drug resistance into focus. The aim of this study was to investigate the distribution and antimicrobial susceptibility of S. maltophilia isolates obtained from various clinical samples in our hospital for a period of eight years. Method: Antimicrobial resistance rates of 149 strains of S. maltophilia isolated from various clinical samples between January 2011 and December2019 were investigated. Bacterial identification and antibiotic susceptibility were performed with routine conventional microbiological methods and the VITEK 2 compact automated system (BioMerieux, France). Results: While S. maltophilia was most frequently isolated in intensive care units, from a total of 50 samples (33.5%), the rate was 0.6% (1 sample) the cardio vascular surgery service and pediatrics services. 85 (57%) of the samples were respiratory tract isolates (tracheal aspirate, lavage, sputum) with at least 1 (0.6%) pleural and joint fluid. Among these isolates of S maltophilia, which shows natural resistance to carbapenems, resistance for levofloxacin was 6% and for trimethoprim/ sulfamethoxazole was 12%. Conclusion: Due to the high resistance rates observed in the study, in vitro susceptibility tests should be used as much as possible in the treatment of nosocomial infections caused by S. maltophilia strains. In cases where this is not possible and empirical treatment is required, trimethoprim-sulfamethoxazole and levofloxacin are reasonable treatment options. Also, before starting treatment, the separation between colonization and agent should be decided in accordance with the clinical findings.

PDF

___

1. Pien C, Kuo H, Chang S, et al. Risk factors for levofloxacin resistance in Stenotrophomonas maltophilia from respiratory tract in a regional hospital. J Microbiol Immunol Infect 2015; 48: 291–5.
2. LevinsonW, Rewiew of Medical Microbiology and Immunology McGraw-Hill14rd. Edn California 2018; 18: 165,661.
3. Guyot A, Turton J, Garner D. Outbreak of Stenotrophomonas maltophilia on an intensive care unit. J HospInfect 2013; 85: 303–7.
4. Garazi M, Singer C, Tai J, et al. Blood stream infections caused by Stenotrophomonas maltophilia: a seven year review. J HospInfect 2012; 81: 114–8.
5. Wood G, Underwood E, Croce M, et al. Treatment of recurrent Stenotrophomonas maltophilia ventilator associated pneumonia with doxycycline and aerosolized colistin. Ann Pharmac other 2010; 44: 1665–8.
6. Saugel B, Eschermann K, Hoffmann R, et al. Stenotrophomonas maltophilia in the respiratory tract of medial intensive care unit patients. Eur J Clin Microbiol Infect Dis 2012; 31: 1419 –28.
7. Brooke J.Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev 2012;25:2-41.
8. Gallo SW, Ramos PL, Ferreira CAS, et al. A specific polymerase chain reaction method to identify Stenotrophomonas maltophilia. MemInst Oswaldo Cruz. 2013; 108: 390–1.
9. Esposito A, Pompilio A, Bettua C, et al. Evolution of Stenotrophomonas maltophilia in cystic fibrosis lung over chronic infection: a genomic and phenotypic population study. Front Microbiol. 2017; 8: 1590.
10. Kandemir I, Özcan N, Alanbayı Ü, ve ark. Klinik Örneklerden İzole Edilen Stenotrophomonas maltophilia Suşlarının Dağılımı ve Antimikrobiyal Duyarlılıkları, Dicle Medical Journal 2016; 43: 237-40.
11. Nseir S, DiPompeo C, Brisson H, et al. Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome. CritCare. 2006; 10: R143.
12. Metan G, Hayran M, Hascelik G, Uzun O. Which patient is a candidate for empirical therapy against Stenotrophomonas maltophilia bacteraemia? An analysis of associated risk factors in a tertiary care hospital. Scand J InfectDis. 2006; 38: 527–31.
13. Hanes SD, Demirkan K, Tolley E, et al. Risk factors for late-onset nasocomial pneumonia caused by Stenotrophomonas maltophilia in criticallyill trauma patients. ClinInfectDis. 2002; 35: 228–35.
14. Avcı M, Özgenç O, Coşkuner SA, et al. Hastane Kökenli Stenotrophomonas maltophilia İnfeksiyonlarının Değerlendirilmesi. FLORA 2010; 15: 153-9.
15. Sader HS, Jones RN. Antimicrobial susceptibility of uncommonly isolated non-enteric gram-negative bacilli. Int J Antimicrob Agents 2005; 25: 95-109.
16. Toleman MA, Bennett PM, Bennett DM, et al. Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sulgenes. Emerg Infect Dis2007; 13: 559-65.
17. Fedler KA, Biedenbach DJ, Jones RN. Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents. Diagn Microbiol Infect Dis 2006; 56: 427- 43.
18. Tekin A, Dal T, Tekin R, et al. Klinik Örneklerden İzole Edilen Stenotrophomonas maltophilia Suşlarının İn Vitro Antibiyotik Duyarlılık Paterni. Düzce Tıp Fakültesi Dergisi 2014; 16: 4.
19. Guerci P, Bellut H, Mokhtari M, et al. Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nation wide retrospective study.Critical Care 2019 23:371 https://doi.org/10.1186/s13054-019-2649-5
20. Valdezate S, Vindel A, Loza E, et al. Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains. Antimicrob Agents Chemother 2001; 45: 1581-4.
21. Türk Dağı H, Arslan U, Tuncer İ. Kan kültürlerinden izole edilen Stenotrophomonas maltophilias uşlarının antibiyotik direnci. Ankem Dergisi 2011; 25: 27-30.
22. Pompilio A, Savini V, et al. Clonal Diversity, Biofilm Formation, and Antimicrobial Resistance among Stenotrophomonas maltophilia Strains from Cystic Fibrosis and Non-Cystic Fibrosis Patients. Antibiotics (Basel). 2020 Jan 2; 9. pii: E15. doi: 10.3390/ antibiotics9010015
23. Farrell DJ, Sader HS, Jones RN. Antimicrobial susceptibility of a world wide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob Agents Chemother 2010; 54: 2735-7.
24. Wu H, Wang JT, Shiau YR, et al. A multi center surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan. J Microbiol Immunol Infect 2012; 45: 120126.
25. Dizbay M, Tunçcan ÖG, Maral I, et al. Five year surveillance of nosocomial Stenotrophomonas maltophilia infections in Gazi University Hospital. Turkiye Klinikleri J MedSci 2009; 29: 1406-11.
26. Hsueh S.C, Lee Y, Huang Y.T et al. Invitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/ avibactamandother comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with blood stream infections in Taiwan Antimicrob Chemother 2019; 74: 380–6.
27. Ismail N, Zam Z, Hassan S. A, et al. A Combination of Trimethoprim-sulfamethoxazole and Ceftazidime Showed Good InVitro Activity against Stenotrophomonas maltophilia Malays J Med Sci. Mar– Apr 2017; 24: 21–7.